Plasma Aldosterone and Heart Failure in the General Community

Abstract

and 687pg/ml, respectively. BNP decreased in both groups at discharge (60% for MSASV vs. 40% for standard care). However, after 3 days, BNP in the standard care group had increased to a median of 920pg/ml, while BNP in the MV-ASV group demonstrated a continued and marked decrease to a median of 353pg/ml. Compared to admission, the 3 day Likert Breathing scores demonstrated an average 52% increase in the MV-ASV group, versus a 24% increase in the standard care group. Conclusion: The use of MV-ASV in patients with ADHF resulted in a rapid early improvement in dyspnea as well as a marked drop in BNP levels, suggesting mitigations of pulmonary edema and neurohormonal activity.